<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35335272</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Computational Screening of Newly Designed Compounds against Coxsackievirus A16 and Enterovirus A71.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1908</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules27061908</ELocationID><Abstract><AbstractText>Outbreaks of hand, foot, and mouth disease (HFMD) that occur worldwide are mainly caused by the Coxsackievirus-A16 (CV-A16) and Enterovirus-A71 (EV-A71). Unfortunately, neither an anti-HFMD drug nor a vaccine is currently available. Rupintrivir in phase II clinical trial candidate for rhinovirus showed highly potent antiviral activities against enteroviruses as an inhibitor for 3C protease (3Cpro). In the present study, we focused on designing 50 novel rupintrivir analogs against CV-A16 and EV-A71 3Cpro using computational tools. From their predicted binding affinities, the five compounds with functional group modifications at P1', P2, P3, and P4 sites, namely P1'-1, P2-m3, P3-4, P4-5, and P4-19, could bind with both CV-A16 and EV-A71 3Cpro better than rupintrivir. Subsequently, these five analogs were studied by 500 ns molecular dynamics simulations. Among them, P2-m3, the derivative with meta-aminomethyl-benzyl group at the P2 site, showed the greatest potential to interact with the 3Cpro target by delivering the highest number of intermolecular hydrogen bonds and contact atoms. It formed the hydrogen bonds with L127 and K130 residues at the P2 site stronger than rupintrivir, supported by significantly lower MM/PB(GB)SA binding free energies. Elucidation of designed rupintrivir analogs in our study provides the basis for developing compounds that can be candidate compounds for further HFMD treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sripattaraphan</LastName><ForeName>Amita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Structural and Computational Biology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanachai</LastName><ForeName>Kamonpan</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2605-5360</Identifier><AffiliationInfo><Affiliation>Structural and Computational Biology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavasiri</LastName><ForeName>Warinthorn</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boonyasuppayakorn</LastName><ForeName>Siwaporn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Applied Medical Virology Research Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maitarad</LastName><ForeName>Phornphimon</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0035-0070</Identifier><AffiliationInfo><Affiliation>Research Center of Nano Science and Technology, Shanghai University, Shanghai 200444, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rungrotmongkol</LastName><ForeName>Thanyada</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Structural and Computational Biology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ph.D. Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GCUGR1125633083M</GrantID><Agency>90th Anniversary of Chulalongkorn University Fund</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3C protease</Keyword><Keyword MajorTopicYN="N">coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">hand foot and mouth disease</Keyword><Keyword MajorTopicYN="N">in silico drug design</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35335272</ArticleId><ArticleId IdType="pmc">PMC8955072</ArticleId><ArticleId IdType="doi">10.3390/molecules27061908</ArticleId><ArticleId IdType="pii">molecules27061908</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu R.N., Qian Y., Deng J., Xing J.F., Zhao L.Q., Wang F., Liao B., Ren X.X., Li Y., Zhang Q. Study on the association of hand, foot and mouth disease and enterovirus 71/CA16 among children in Beijing, 2007. Zhonghua Liu Xing Bing Xue Za Zhi (Zhonghua Liuxingbingxue Zazhi) 2007;28:1004–1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">18399150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano T., Makino N., Aoyama Y., Ae R., Kojo T., Kotani K., Yanagawa H. Temporal and geographical clustering of Kawasaki disease in Japan: 2007–2012. Pediatr. Int. 2016;58:1140–1145. doi: 10.1111/ped.12970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ped.12970</ArticleId><ArticleId IdType="pubmed">26940079</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K.Y., Zhang X., Chung P.H., Tsao K.C., Lin T.Y., Su L.H., Chiu C.H. Enterovirus 71 in Taiwan, 2004–2006: Epidemiological and virological features. Scand. J. Infect. Dis. 2008;40:571–574. doi: 10.1080/00365540701799359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365540701799359</ArticleId><ArticleId IdType="pubmed">18584550</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.P., Goh K.T., Chong C.Y., Teo E.S., Lau G., Ling A.E. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg. Infect. Dis. 2003;9:78. doi: 10.3201/eid1301.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Chieochansin T., Linsuwanon P., Korkong S., Thongkomplew S., Vichaiwattana P., Theamboonlers A., Poovorawan Y. Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012. Emerg. Infect. Dis. 2013;19:641. doi: 10.3201/eid1904.121666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1904.121666</ArticleId><ArticleId IdType="pmc">PMC3647428</ArticleId><ArticleId IdType="pubmed">23631943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarma N. Hand, foot, and mouth disease: Current scenario and Indian perspective. Indian J. Dermatol. Venereol. Leprol. 2013;79:165–175. doi: 10.4103/0378-6323.107631.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0378-6323.107631</ArticleId><ArticleId IdType="pubmed">23442455</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M.T., Cheng Y.H., Liu Y.N., Liao N.C., Lu W.W., Kung S.H. Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob. Agents Chemother. 2019;53:748–755. doi: 10.1128/AAC.00841-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00841-08</ArticleId><ArticleId IdType="pmc">PMC2630644</ArticleId><ArticleId IdType="pubmed">19015331</ArticleId></ArticleIdList></Reference><Reference><Citation>Omaña-Cepeda C., Martínez-Valverde A., Del Mar Sabater-Recolons M., Jané-Salas E., Marí-Roig A., López-López J. A literature review and case report of hand, foot and mouth disease in an immunocompetent adult. BMC Res. Notes. 2016;9:165. doi: 10.1186/s13104-016-1973-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-016-1973-y</ArticleId><ArticleId IdType="pmc">PMC4791924</ArticleId><ArticleId IdType="pubmed">26975350</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra A.M., Orille E., Waseem M. Hand Foot and Mouth Disease, StatPearls.  [(accessed on 24 October 2021)];2021  Available online:  https://www.ncbi.nlm.nih.gov/books/NBK431082/</Citation></Reference><Reference><Citation>Ji T., Han T., Tan X., Zhu S., Yan D., Yang Q., Song Y., Cui A., Zhang Y., Mao N., et al. Surveillance, epidemiology, and pathogen spectrum of hand, foot, and mouth disease in mainland of China from 2008 to 2017. Biosafety Health. 2019;1:32–40. doi: 10.1016/j.bsheal.2019.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bsheal.2019.02.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Long L., Xu L., Xiao Z., Hu S., Luo R., Wang H., Lu X., Xu Z., Yao X., Zhou L., et al. Neurological complications and risk factors of cardiopulmonary failure of EV-A71-related hand, foot and mouth disease. Sci. Rep. 2016;6:23444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4802311</ArticleId><ArticleId IdType="pubmed">27001010</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Silva E.E., Winkler M.T., Pallansch M.A. Role of enterovirus 71 in acute flaccid paralysis after the eradication of poliovirus in Brazil. Emerg. Infect. Dis. 1996;2:231–233. doi: 10.3201/eid0203.960312.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0203.960312</ArticleId><ArticleId IdType="pmc">PMC2626804</ArticleId><ArticleId IdType="pubmed">8903236</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G., Qi J., Chen Z., Xu X., Gao F., Lin D., Qian W., Liu H., Jiang H., Yan J., et al. Enterovirus 71 and coxsackievirus A16 3C proteases: Binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 2011;85:10319–10331. doi: 10.1128/JVI.00787-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Fan T., Yao X., Wu Z., Guo L., Lei X., Wang M., Jin Q., Cui S. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J. Virol. 2011;85:10021–10030. doi: 10.1128/JVI.05107-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05107-11</ArticleId><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C.J., Shie J.J., Fang J.M., Yen G.R., Hsu J.T.A., Liu H.G., Tseng S.N., Chang S.C., Lee C.Y., Shih S.R., et al. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg. Med. Chem. 2008;16:7388–7398. doi: 10.1016/j.bmc.2008.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2008.06.015</ArticleId><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Binford S.L., Brothers M.A., Jackson R.L., Ford C.E., Diem M.D., Maldonado F., Dragovich P.S., Zhou R., Prins T.J., et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 1999;43:2444–2450. doi: 10.1128/AAC.43.10.2444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.10.2444</ArticleId><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi M.H., Wong S.C., Lewthwaite P., Cardosa M.J., Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097–1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.C., Shih S.R., Chang T.Y., Tseng H.Y., Shih Y.F., Yen K.J., Chen W.C., Shie J.J., Fang J.M., Liang P.H., et al. A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71. Anal. Biochem. 2008;375:115–123. doi: 10.1016/j.ab.2007.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2007.12.019</ArticleId><ArticleId IdType="pubmed">18190777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Song Z., Qin B., Zhang X., Chen L., Hu Y., Yuan Z. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: Evaluation of antiviral efficacy in a murine infection model. Antivir. Res. 2013;97:264–269. doi: 10.1016/j.antiviral.2012.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.029</ArticleId><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford S.L., Maldonado F., Brothers M.A., Weady P.T., Zalman L.S., Meador J.W., Matthews D.A., Patick A.K. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 2005;49:619–626. doi: 10.1128/AAC.49.2.619-626.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.2.619-626.2005</ArticleId><ArticleId IdType="pmc">PMC547258</ArticleId><ArticleId IdType="pubmed">15673742</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews D.A., Dragovich P.S., Webber S.E., Fuhrman S.A., Patick A.K., Zalman L.S., Hendrickson T.F., Love R.A., Prins T.J., Marakovits J.T., et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. USA. 1999;96:11000–11007. doi: 10.1073/pnas.96.20.11000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11000</ArticleId><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., Patick A.K., Smith G.J., III, Zalman L.S. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob. Agents Chemother. 2003;47:3907–3916. doi: 10.1128/AAC.47.12.3907-3916.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.12.3907-3916.2003</ArticleId><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 1974;129:304–309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Meijer A., Froeyen M., Zhang L., Thibaut H.J., Baggen J., George S., Vernachio J., Van Kuppeveld F.J.M., Leyssen P., et al. Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob. Agents Chemother. 2015;59:7782–7785. doi: 10.1128/AAC.01375-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01375-15</ArticleId><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P.S., Prins T.J., Zhou R., Webber S.E., Marakovits J.T., Fuhrman S.A., Patick A.K., Matthews D.A., Lee C.A., Ford C.E., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 1999;42:1213–1224. doi: 10.1021/jm9805384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9805384</ArticleId><ArticleId IdType="pubmed">10197965</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix C., George S., Leyssen P., Hilgenfeld R., Neyts J. The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir. Antimicrob. Agents Chemother. 2015;59:5814–5818. doi: 10.1128/AAC.00534-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00534-15</ArticleId><ArticleId IdType="pmc">PMC4538484</ArticleId><ArticleId IdType="pubmed">26055377</ArticleId></ArticleIdList></Reference><Reference><Citation>Jetsadawisut W., Nutho B., Meeprasert A., Rungrotmongkol T., Kungwan N., Wolschann P., Hannongbua S. Susceptibility of inhibitors against 3C protease of coxsackievirus A16 and enterovirus A71 causing hand, foot and mouth disease: A molecular dynamics study. Biophys. Chem. 2016;219:9–16. doi: 10.1016/j.bpc.2016.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpc.2016.09.005</ArticleId><ArticleId IdType="pubmed">27668727</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cao L., Zhai Y., Yin Z., Sun Y., Shang L. Structure of the Enterovirus 71 3C Protease in Complex with NK-1.8 k and Indications for the Development of Antienterovirus Protease Inhibitor. Antimicrob. Agents Chemother. 2017;61:e00298-17. doi: 10.1128/AAC.00298-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00298-17</ArticleId><ArticleId IdType="pmc">PMC5487676</ArticleId><ArticleId IdType="pubmed">28461310</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrand P.W., Rose A.S., Tiemann J.K. Bringing molecular dynamics simulation data into view. Trends Biochem. Sci. 2019;44:902–913. doi: 10.1016/j.tibs.2019.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2019.06.004</ArticleId><ArticleId IdType="pubmed">31301982</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X.D., Tong Y., Wei Z.N., Wang L., Mai J.Y., Wu Y., Luo Z.-Y., Li S., Li M., Wang S., et al. Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China. Sci. Rep. 2020;10:20909. doi: 10.1038/s41598-020-77768-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77768-7</ArticleId><ArticleId IdType="pmc">PMC7708472</ArticleId><ArticleId IdType="pubmed">33262488</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson M.H., Søndergaard C.R., Rostkowski M., Jensen J.H. PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions. J. Chem. Theory Comput. 2011;7:525–537. doi: 10.1021/ct100578z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct100578z</ArticleId><ArticleId IdType="pubmed">26596171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleiziffer P., Schaller K., Riniker S. Machine learning of partial charges derived from high-quality quantum-mechanical calculations. J. Chem. Inf. Modeling. 2018;58:579–590. doi: 10.1021/acs.jcim.7b00663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.7b00663</ArticleId><ArticleId IdType="pubmed">29461814</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKerell A.D., Jr. Empirical force fields for biological macromolecules: Overview and issues. J. Comput. Chem. 2004;25:1584–1604. doi: 10.1002/jcc.20082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20082</ArticleId><ArticleId IdType="pubmed">15264253</ArticleId></ArticleIdList></Reference><Reference><Citation>Case D.A., Cheatham T.E., III, Darden T., Gohlke H., Luo R., Merz K.M., Jr., Onufriev A., Simmerling C., Wang B., Woods R.J. The Amber biomolecular simulation programs. J. Comput. Chem. 2005;26:1668–1688. doi: 10.1002/jcc.20290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20290</ArticleId><ArticleId IdType="pmc">PMC1989667</ArticleId><ArticleId IdType="pubmed">16200636</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisch M.J.E.A. Gaussian09. 2009.  [(accessed on 16 July 2021)].  Available online:  http://www.gaussian.com/</Citation></Reference><Reference><Citation>Case D.A., Babin V., Berryman J.T., Betz R.M., Cai Q., Cerutti D.S., Cheatham T.E., Darden I.T.A., Duke R.E., Gohlke H., et al. AMBER 16. University of California; San Francisco, CA, USA: 2016.</Citation></Reference><Reference><Citation>Da Silva A.W.S., Vranken W.F. ACPYPE-Antechamber python parser interface. BMC Res. Notes. 2012;5:1–8. doi: 10.1186/1756-0500-5-367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-0500-5-367</ArticleId><ArticleId IdType="pmc">PMC3461484</ArticleId><ArticleId IdType="pubmed">22824207</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier J.A., Martinez C., Kasavajhala K., Wickstrom L., Hauser K.E., Simmerling C. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 2015;11:3696–3713. doi: 10.1021/acs.jctc.5b00255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.5b00255</ArticleId><ArticleId IdType="pmc">PMC4821407</ArticleId><ArticleId IdType="pubmed">26574453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Wolf R.M., Caldwell J.W., Kollman P.A., Case D.A. Development and testing of a general amber force field. J. Comput. Chem. 2004;25:1157–1174. doi: 10.1002/jcc.20035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20035</ArticleId><ArticleId IdType="pubmed">15116359</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983;79:926–935. doi: 10.1063/1.445869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.445869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittayanarakul K., Aruksakunwong O., Saen-oon S., Chantratita W., Parasuk V., Sompornpisut P., Hannongbua S. Insights into saquinavir resistance in the G48V HIV-1 protease: Quantum calculations and molecular dynamic simulations. Biophys. J. 2005;88:867–879. doi: 10.1529/biophysj.104.046110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.104.046110</ArticleId><ArticleId IdType="pmc">PMC1305161</ArticleId><ArticleId IdType="pubmed">15542562</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., George S., Kusov Y., Perbandt M., Anemüller S., Mesters J.R., Hilgenfeld R. 3C protease of enterovirus 68: Structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J. Virol. 2013;87:4339–4351. doi: 10.1128/JVI.01123-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01123-12</ArticleId><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapp B., Frantal S., Cibena M., Schreiner W., Bauer P. Is an intuitive convergence definition of molecular dynamics simulations solely based on the root mean square deviation possible? J. Comput. Biol. 2011;18:997–1005. doi: 10.1089/cmb.2010.0237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cmb.2010.0237</ArticleId><ArticleId IdType="pmc">PMC3145956</ArticleId><ArticleId IdType="pubmed">21702691</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe D.R., Cheatham T.E., III PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 2013;9:3084–3095. doi: 10.1021/ct400341p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct400341p</ArticleId><ArticleId IdType="pubmed">26583988</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>